Researchers from Pompeu Fabra University, Verge de la Cinta Hospital in Tortosa, Rovira i Virgili University and the Catalunya Sud Biomedical Research Institute have built an AI model that, for the first time, combines tumour data with the patient's immune response.
It is the first large randomised trial of AI in breast cancer screening: 106,000 women in Sweden. The final results, in The Lancet, also show 12% fewer cancers appearing between screenings and 27% fewer of the most aggressive types.
Insilico Medicine's rentosertib is now being tested in about 320 patients with idiopathic pulmonary fibrosis, a serious disease that scars the lungs. In the previous phase, the highest dose improved lung capacity while it worsened in the placebo group.
